CancerDR

CancerDR catalogs mutation and pharmacological profiles from COSMIC and CCLE to characterize how mutations in drug targets influence anti-cancer drug efficacy across 148 anti-cancer drugs and 952 distinct cancer cell lines.

Key Features:

• Data integration from COSMIC and CCLE: Integrates mutation data and pharmacological profiles derived from the Catalogue Of Somatic Mutations In Cancer (COSMIC) and the Cancer Cell Line Encyclopedia (CCLE).
• Coverage of drugs and cell lines: Profiles interactions of 148 anti-cancer drugs across 952 distinct cancer cell lines.
• Drug target information: Provides sequences of natural variants, documented mutations associated with resistance or sensitivity, tertiary structural information of protein targets, and alignment profiles for mutants and variants.
• Identification of promiscuous drug molecules: Supports identification of drugs with broad-spectrum activity across multiple cancer cell lines.

Scientific Applications:

• Analysis of drug resistance mechanisms: Maps mutations in drug targets to resistance or sensitivity phenotypes to elucidate acquired resistance mechanisms.
• Personalized therapy guidance: Informs selection or design of therapies tailored to patient-specific target mutations and drug-response profiles.
• Discovery of broad-spectrum therapeutics: Identifies candidate promiscuous drugs that retain efficacy across diverse cancer cell lines to address resistance.
• Comparative drug-target profiling: Enables comparative analysis of drug-target interactions across 952 cancer cell lines to assess variability in response.

Methodology:

Integration of mutation and pharmacological data from COSMIC and CCLE with generation of sequence variant records, alignment profiles for mutants and tertiary structural annotations of protein targets.